Li Yu - Mar 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role: VP Cntrllr/Prncpl Acctng Offcr
Signature: /s/ Li Yu
Stock symbol: OCX
Transactions as of: Mar 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/17/2022, 09:29 PM
Previous filing: Oct 14, 2021
Next filing: May 19, 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Award	$0	+37.5K		$0.00	37.5K	Mar 15, 2022	Common Stock	37.5K	$1.15	Direct	F1
transaction	OCX	Option to Purchase Common Stock	Award	$0	+37.5K		$0.00	37.5K	Mar 15, 2022	Common Stock	37.5K	$1.15	Direct	F2

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2	Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.